EFTR
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Effector Therapeutics Inc (EFTR) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Profitability (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | B+ (3.5) | D+ (1.7) | C (2.4) | C- (1.9) | C (2.5) |
| 2026-08-04 | C+ (2.7) | B+ (3.5) | D+ (1.7) | C (2.4) | C- (1.9) | C (2.5) |
| 2026-08-03 | C+ (2.7) | C+ (2.8) | C- (2.1) | C (2.4) | C- (2.0) | C (2.4) |
| 2026-08-02 | C+ (2.7) | C+ (2.8) | C- (2.1) | C (2.4) | C- (1.9) | C (2.4) |
| 2022-12-31 | C+ (2.5) | A+ (4.9) | D+ (1.6) | A+ (4.6) | D (1.5) | B- (3.0) |